Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XmAb18968 |
Synonyms | |
Therapy Description |
XmAb18968 is a bispecific T-cell engager that targets both CD38 and CD3, potentially leading to a cytotoxic T-lymphocyte mediated response against tumor cells expressing CD38 (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2515; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XmAb18968 | XmAb-18968|XmAb 18968 | CD3 Antibody 99 CD38 Antibody 20 | XmAb18968 is a bispecific T-cell engager that targets both CD38 and CD3, potentially leading to a cytotoxic T-lymphocyte mediated response against tumor cells expressing CD38 (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2515; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |